Improvement of tumor targeting and antitumor activity by a disulphide bond stabilized diabody expressed in Escherichia coli

Cancer Immunology, Immunotherapy

Volumn 58, Issue 11, 2009, Pages 1763-1771

  Liu, Juanni ^a   Yang, Ming ^a   Wang, Jinhong ^a   Xu, Yuanfu ^a   Wang, Yan ^b   Shao, Xiaofeng ^a   Yang, Chunzheng ^a   Gao, Yingdai ^a   Xiong, Dongsheng ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Antibody engineering; Bispecific diabody; Cancer therapy; Diabody; Drug stability; P glycoprotein

Indexed keywords

ANTIBODY; CD3 ANTIBODY; CYSTEINE; DIMER; GLYCOPROTEIN P; PGP ANTIBODY; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD3 ANTIGEN; DISULFIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DISULFIDE BOND; ESCHERICHIA COLI; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; CELL STRAIN K 562; CHEMISTRY; DRUG SCREENING; DRUG STABILITY; GENETICS; IMMUNOLOGY; NEOPLASM;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; CELL LINE; DISULFIDES; DRUG STABILITY; ESCHERICHIA COLI; FEMALE; HUMANS; K562 CELLS; MICE; MICE, INBRED BALB C; NEOPLASMS; P-GLYCOPROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349786183     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0684-9     Document Type: Article

References (42)

1. I Benhar I Pastan 1995 Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice Clin Cancer Res 1 1023 1029
2. TK Bera M Onda U Brinkmann I Pastan 1998 A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2 J Mol Biol 281 475 483
3. U Brinkmann Y Reiter SH Jung B Lee I Pastan 1993 A recombinant immunotoxin containing a disulfide-stabilized Fv fragment Proc Natl Acad Sci USA 90 7538 7542
4. P Buhler P Wolf D Gierschner I Schaber A Katzenwadel W Schultze-Seemann U Wetterauer M Tacke M Swamy WW Schamel U Elsasser-Beile 2008 A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells Cancer Immunol Immunother 57 43 52
5. B Cochlovius SM Kipriyanov MJJG Stassar O Christ J Schuhmacher G Strau G Moldenhauer M Little 2000 Treatment of human B Cell lymphoma xenografts with a CD3 CD19 diabody and T Cells J Immunol 165 888 895
6. TE Creighton 1984 Disulfide bond formation in proteins Methods Enzymol 107 305 329
7. LL de Figueiredo-Pontes MC Pintao LC Oliveira LF Dalmazzo RH Jacomo AB Garcia RP Falcao EM Rego 2008 Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia Cytometry B Clin Cytom 74 163 168
8. KL Deuchars V Ling 1989 P-glycoprotein and multidrug resistance in cancer chemotherapy Semin Oncol 16 156 165
9. T Dreier PA Baeuerle I Fichtner M Grun B Schlereth G Lorenczewski P Kufer R Lutterbuse G Riethmuller P Gjorstrup RC Bargou 2003 T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct J Immunol 170 4397 4402
10. T Dreier G Lorenczewski C Brandl P Hoffmann U Syring F Hanakam P Kufer G Riethmuller R Bargou PA Baeuerle 2002 Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody Int J Cancer 100 690 697
11. JA Endicott V Ling 1989 The biochemistry of P-glycoprotein-mediated multidrug resistance Annu Rev Biochem 58 137 171
12. K FitzGerald P Holliger G Winter 1997 Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris Protein Eng 10 1221 1225
13. Y Gao D Xiong M Yang H Liu H Peng X Shao Y Xu C Xu D Fan L Qin C Yang Z Zhu 2004 Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody Leukemia 18 513 520
14. MM Gottesman I Pastan 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter Annu Rev Biochem 62 385 427
15. H Hayashi R Asano K Tsumoto Y Katayose M Suzuki M Unno H Kodama S Takemura H Yoshida K Makabe K Imai S Matsuno I Kumagai T Kudo 2004 A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells Cancer Immunol Immunother 53 497 509
16. DJ Hicklin FM Marincola S Ferrone 1999 HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story Mol Med Today 5 178 186
17. P Holliger T Prospero G Winter 1993 "Diabodies": small bivalent and bispecific antibody fragments Proc Natl Acad Sci USA 90 6444 6448
18. T Holyoake X Jiang C Eaves A Eaves 1999 Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia Blood 94 2056 2064
19. BJ Huntly DG Gilliland 2005 Leukaemia stem cells and the evolution of cancer-stem-cell research Nat Rev Cancer 5 311 321
20. BJ Huntly DG Gilliland 2005 Leukaemia stem cells and the evolution of cancer-stem-cell research Nat Rev Cancer 5 311 321
21. AK Johnsen DJ Templeton M Sy CV Harding 1999 Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis J Immunol 163 4224 4231
22. M Juweid R Neumann C Paik MJ Perez-Bacete J Sato W van Osdol JN Weinstein 1992 Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier Cancer Res 52 5144 5153
23. T Kageshita S Hirai T Ono DJ Hicklin S Ferrone 1999 Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression Am J Pathol 154 745 754
24. GI Keshet I Goldstein O Itzhaki K Cesarkas L Shenhav A Yakirevitch AJ Treves J Schachter N Amariglio G Rechavi 2008 MDR1 expression identifies human melanoma stem cells Biochem Biophys Res Commun 368 930 936
25. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40(suppl):S3-S8
26. JA Moscow E Schneider SP Ivy KH Cowan 1997 Multidrug resistance Cancer Chemother Biol Response Modif 17 139 177
27. MH Raaijmakers EP de Grouw BA van der Reijden TJ de Witte JH Jansen RA Raymakers 2006 ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia Clin Cancer Res 12 3452 3458
28. RC Rees S Mian 1999 Selective MHC expression in tumours modulates adaptive and innate antitumour responses Cancer Immunol Immunother 48 374 381
29. Y Reiter U Brinkmann SH Jung B Lee PG Kasprzyk CR King I Pastan 1994 Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment J Biol Chem 269 18327 18331
30. Y Reiter RJ Kreitman U Brinkmann I Pastan 1994 Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin Int J Cancer 58 142 149
31. Y Reiter LH Pai U Brinkmann QC Wang I Pastan 1994 Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment Cancer Res 54 2714 2718
32. M Schaich S Soucek C Thiede G Ehninger T Illmer 2005 MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia Br J Haematol 128 324 332
33. DC Shen XF Yang 1993 A high affinity CD3 monoclonal antibody HIT3a Acta Academiae Medicinae Sinicae 15 157 162
34. JC Stinchcombe G Bossi S Booth GM Griffiths 2001 The immunological synapse of CTL contains a secretory domain and membrane bridges Immunity 15 751 761
35. AT Stopeck A Gessner TP Miller EM Hersh CS Johnson H Cui Y Frutiger TM Grogan 2000 Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma Clin Cancer Res 6 3904 3909
36. TP Stromskaya EY Rybalkina SS Kruglov TN Zabotina EB Mechetner AG Turkina AA Stavrovskaya 2008 Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib Biochemistry (Mosc) 73 29 37
37. F Tsukamoto E Shiba T Taguchi T Sugimoto T Watanabe SJ Kim Y Tanji Y Kimoto M Izukura SI Takai 1997 Immunohistochemical Detection of P-glycoprotein in Breast Cancer and Its Significance as a Prognostic Factor Breast Cancer 4 259 263
38. DS Xiong CZ Yang 1999 Generation and characterization of monoclonal antibodies against P-glycoprotein (Pgp) Clin J Hematol 20 326 327
39. CZ Yang FJ Luan DS Xiong BR Liu YF Xu KS Gu 1995 Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin Zhongguo Yao Li Xue Bao 16 333 337
40. T Yokota DE Milenic M Whitlow J Schlom 1992 Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms Cancer Res 52 3402 3408
41. Z Zhu P Rockwell D Lu H Kotanides B Pytowski DJ Hicklin P Bohlen L Witte 1998 Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library Cancer Res 58 3209 3214
42. Z Zhu G Zapata R Shalaby B Snedecor H Chen P Carter 1996 High level secretion of a humanized bispecific diabody from Escherichia coli Biotechnology (NY) 14 192 196